Teva U.S. sales plummet, Copaxone sets record

Generics giant Teva Pharmaceutical Industries ($TEVA) suffered another decline in U.S. sales, dampening third-quarter results. The Israeli company saw net income drop by 12.8% to $916 million, with U.S. revenues dropping by a whopping 48% to $845 million, compared with a period last year marked by several new product launches. Report

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.